Hexarelin, GHRP-2, GHRP-6: the first-generation secretagogues compared
Last updated: October 27, 2026 · 9 min read · By the Grey Peptides Editorial Board
- GHRP-6, GHRP-2 and hexarelin release growth hormone through the ghrelin receptor, and all three also raise the stress hormones ACTH and cortisol. None is a 'clean' growth hormone releaser.
- GHRP-2 is pralmorelin, approved in Japan as a diagnostic test. In seven lean men, an infusion made them eat 35.9% more. Hexarelin's growth hormone response fell by almost half over 16 weeks of twice-daily use.
- Drugs@FDA lists none of them, FDA lists GHRP-6 and GHRP-2 among substances that may present significant safety risks in compounding, and WADA prohibits all three. Their evidence is short studies of hormone levels, not long-term benefits.
Where the GHRPs came from
Researchers at Tulane University led by Cyril Bowers synthesised a series of small peptides that release growth hormone, and pralmorelin (GHRP-2) came from that work and from the German company Polygen; Kaken Pharmaceutical later acquired its rights 1. These peptides act on the receptor for ghrelin, a 28-amino-acid stomach peptide isolated after the GHRPs were made 2 1. Hexarelin was made by replacing a tryptophan of GHRP-6 with the chemically more stable 2-methyl-tryptophan; in rats it released growth hormone about as effectively as GHRP-6 intravenously and slightly more effectively under the skin 3.
Comparing them with ghrelin itself is revealing. In seven young men, ghrelin released significantly more growth hormone than either hexarelin or GHRH, and it raised prolactin, ACTH and cortisol more than hexarelin did 2. These peptides imitate a natural hormone, and like that hormone they act on more than growth hormone.
Side by side
From the studies and regulatory pages cited below, as of October 28, 2026:
| GHRP-6 | GHRP-2 (pralmorelin) | Hexarelin | |
|---|---|---|---|
| Structure | Hexapeptide, His-D-Trp-Ala-Trp-D-Phe-Lys-NH2 4 | Hexapeptide, D-Ala-D-(β-naphthyl)-Ala-Ala-Trp-D-Phe-Lys-NH2 5 | GHRP-6 with 2-methyl-tryptophan in place of D-tryptophan 3 |
| Approval | No FDA application; FDA 503A Category 3 and 503B Category 2 6 7 8 | Approved in Japan as a diagnostic test 9; FDA 503A Category 3 and 503B Category 2 6 7 | No FDA application; not on FDA's 503A or safety-risk lists 8 6 7 |
| Half-life in people | 2.5 hours elimination after an intravenous dose (nine men) 4 | Not reported in the studies cited here | Not reported in the studies cited here |
| Cortisol and ACTH | Raised 10 | Raised; studied as an adrenal test 11 | Raised acutely; the cortisol response shrank with 16 weeks of use 12 13 |
| Prolactin | Not measured in the studies cited here | Not measured in the studies cited here | Raised acutely 2 12; unchanged after 16 weeks 13 |
| Hunger | Not measured in the studies cited here | 35.9% more eaten at a buffet (seven men) 14 | Acute feeding response in six dogs, lost by week 3 of daily use and back by week 6 15 |
| Desensitisation | No long-term human study among those cited here | Response pattern changed with 7 to 30 days of use 16 | GH response fell by almost half over 16 weeks, then recovered 17 |
| Evidence grade | Medium | Medium | Medium |
| WADA | All prohibited at all times (S2.2.4; GHRP-6, GHRP-2 (pralmorelin) and examorelin (hexarelin) are named) 18 | ||
Growth hormone release
All three release growth hormone strongly. In 12 healthy men, single intravenous doses of hexarelin (0.5, 1 and 2 µg/kg) raised growth hormone to mean peaks of 26.9, 52.3 and 55.0 ng/mL about 30 minutes later, against 3.9 on placebo, in a study whose first author worked for the drug company Mediolanum Farmaceutici 19. GHRP-2 at 100 micrograms intravenously produced a growth hormone peak within 60 minutes in all of 77 healthy adults, averaging 84.6 µg/L, while responses were far lower in 58 patients with severe deficiency, the basis of its validation as an alternative to the insulin tolerance test 20. Four intravenous GHRP-6 doses given in the night raised average growth hormone between 10 pm and 3 am to 15.4 ng/mL, against 5.5 on a placebo night 10, and in seven children with short stature, GHRP-6 by mouth produced a growth hormone response similar to intravenous GHRH 21. GHRP-6 also kept working where GHRH faltered: in 11 people with primary hypothyroidism it released about three times as much growth hormone as GHRH did 22, and in nine people on steroid drugs GHRH barely worked while the response to GHRP-6 matched that of controls; in six with endogenous cortisol excess the GHRP-6 response was reduced too 23.
Cortisol and ACTH: the side effect they share
Unlike GHRH, the GHRPs also stimulate the stress-hormone axis. On nights with GHRP-6 injections, ACTH averaged 21.0 pg/mL against 16.6 on placebo, and cortisol 56.0 ng/mL against 25.2 10. In six people with Addison's disease taking replacement steroids, GHRP-6 produced an ACTH response about 30 times larger than in seven controls, an increase that was not maintained after 72 hours off their steroids 24. GHRP-2's effect on cortisol is reliable enough that, in 47 patients, a peak cortisol below 11.6 µg/dL after GHRP-2 identified secondary adrenal insufficiency with 89.7% sensitivity and 88.9% specificity 11. Hexarelin raised ACTH and cortisol during the night in a sleep study 12, and with twice-daily injections for 16 weeks the cortisol response to the morning dose shrank and recovered four weeks after stopping, with no change in 24-hour urinary cortisol or prolactin 13.
FDA lists GHRP-6 among substances that may present significant safety risks in compounding, citing possible effects on cortisol and higher blood glucose through lower insulin sensitivity; for GHRP-2 it cites reports of serious adverse events, including a higher insulin requirement, deaths of critically ill study subjects, infection and pancreatitis, though causality has not been established 7.
Hunger: what the studies measured
Ghrelin stimulates appetite and meal initiation as well as growth hormone, so peptides that act on its receptor might be expected to increase appetite 14. The clearest test was with GHRP-2: seven lean healthy men given a GHRP-2 infusion for four and a half hours before a buffet ate 35.9% more than on saline, every one of them increased intake, and the mix of foods did not change 14. None of the GHRP-6 studies cited here measured food intake. For hexarelin, the one feeding measurement cited here is in six beagles: an acute feeding response that disappeared by the third week of twice-daily injections and returned by the sixth 15.
Desensitisation: the effect that fades
Hexarelin has the best human data on what happens with repeated use. Older adults injecting it twice daily for 16 weeks saw the growth hormone response to a test dose fall from 19.1 µg/L·h at baseline to 12.3 at week 4 and 10.5 at week 16, recovering to 19.4 four weeks after stopping; IGF-1, body fat, lean mass and bone density did not change significantly 17. In beagles given hexarelin twice daily for six weeks, the response rose at first, then fell below its starting level by week 6 15. GHRP-2 given for 7 to 30 days changed the way it combined with GHRH, from additive to synergistic, and its authors wrote that whether the response desensitises depends partly on dose and frequency 16. The practical meaning is that, in the one long human study, the growth hormone response to hexarelin weakened with continued use and the measured body changes did not follow 17.
Hexarelin and the heart
Hexarelin has an unusual cardiac story. In seven men given intravenous growth hormone or hexarelin, both raised circulating growth hormone to the same extent, but only hexarelin raised the heart's ejection fraction, from 64.0% to 70.7%, within 15 to 30 minutes and lasting up to an hour 25. In seven men with growth hormone deficiency who barely released growth hormone in response, ejection fraction still rose, from 50% to 57% 26. The authors suggested the effect is independent of growth hormone and runs through receptors in the heart 25 26. These are acute, small studies, not evidence that hexarelin helps heart disease.
Sleep and other effects
In the two sleep studies cited here, neither peptide deepened sleep. Four night-time doses of GHRP-6 increased stage 2 sleep and left slow-wave sleep unchanged 10. Four night-time doses of hexarelin in seven young volunteers reduced stage 4 sleep in the first half of the night and EEG delta power across the night, while raising growth hormone, prolactin, ACTH and cortisol 12. In 33 men with prolonged critical illness, five days of GHRP-2 infusion reactivated growth hormone secretion and normalised IGF-1 and related proteins, but the metabolic benefits seen when it was combined with TRH and GnRH were absent with GHRP-2 alone, and lactate and white cell counts rose 27. In an uncontrolled study of 15 children with short stature, intranasal GHRP-2 raised height velocity from 3.7 to about 6 cm a year 28. Treatment development for short stature in Japan and for growth hormone deficiency in the US had reached phase 2 by 2004, and the US programme appeared to have been discontinued 1.
The pralmorelin naming problem
GHRP-2's international nonproprietary name is pralmorelin. In Japan, Kaken Pharmaceutical's injection is labelled for the diagnosis of growth hormone deficiency, given once intravenously (100 µg in adults) 9, the dose validated in the 2007 study 20. A product labelled 'GHRP-2' for research is not that diagnostic, and the Japanese approval covers only the diagnostic injection 9. Our entry lists both names so that searches for either lead to the same evidence.
Regulatory and sport status
Drugs@FDA lists no application for any of the three 8. FDA's list of substances nominated for 503A compounding (updated May 14, 2026) places GHRP-6 and GHRP-2 in Category 3, nominated without adequate support; hexarelin is not on it 6. FDA's safety-risks page (content current as of April 22, 2026) has listed both in 503B Category 2 since September 29, 2023 7. WADA's 2026 Prohibited List names all three under S2.2.4, prohibited at all times 18, and a doping-control method detected unchanged GHRP-2 and its metabolite in the urine of all ten men given it intravenously 5. GHRP-6's elimination half-life in nine healthy men, measured by researchers at Cuba's Center for Genetic Engineering and Biotechnology, was 2.5 hours 4.
How they compare (as of October 28, 2026)
GHRP-2 is the only one of the three approved anywhere, as a diagnostic in Japan 9, and the only one with a controlled human appetite measurement 14. Hexarelin is the best studied for desensitisation, which halved its effect over months without changing body composition 17, and it has acute cardiac effects in small studies 25. GHRP-6 has a measured half-life and many short physiological studies 4. All three raise cortisol, none of the studies cited here shows a long-term muscle, fat-loss or anti-ageing benefit, and all are prohibited in sport 18. Our GHRP-2 vs GHRP-6 and hexarelin vs ipamorelin pages cover the pairs in more detail.
Frequently asked questions
What is the difference between GHRP-2 and GHRP-6?
Both release growth hormone through the ghrelin receptor and raise cortisol. GHRP-2 made seven men eat 35.9% more in a buffet study and is approved in Japan as pralmorelin for diagnosis; Drugs@FDA lists neither.
Does GHRP-6 make you hungry?
It acts on the ghrelin receptor, but none of the GHRP-6 studies cited here measured food intake. GHRP-2, a close relative, increased food intake by 35.9% in a controlled study of seven men.
Is hexarelin stronger than GHRP-6?
In rats it was about as effective intravenously and slightly more effective under the skin. In people its growth hormone response fell by almost half over 16 weeks of twice-daily use and recovered after stopping.
Are GHRPs legal?
Drugs@FDA lists none of them, FDA lists GHRP-6 and GHRP-2 in 503B Category 2 for possible safety risks, and WADA prohibits all three at all times.
Related on Grey Peptides
Sources
- Drugs in R&D (2004). Pralmorelin: GHRP 2, GPA 748, growth hormone-releasing peptide 2, KP-102 D, KP-102 LN, KP-102D, KP-102LN. Drugs R D, 5(4), 236-9 (unsigned drug-development profile). PubMed
- Arvat, E., et al. (2001). Endocrine activities of ghrelin, a natural growth hormone secretagogue (GHS), in humans: comparison and interactions with hexarelin, a nonnatural peptidyl GHS, and GH-releasing hormone. J Clin Endocrinol Metab, 86(3), 1169-74. PMID: 11238504
- Deghenghi, R., et al. (1994). GH-releasing activity of Hexarelin, a new growth hormone releasing peptide, in infant and adult rats. Life Sci, 54(18), 1321-8. PMID: 7910650
- Cabrales, A., et al. (2013). Pharmacokinetic study of Growth Hormone-Releasing Peptide 6 (GHRP-6) in nine male healthy volunteers. Eur J Pharm Sci, 48(1-2), 40-6. PMID: 23099431
- Okano, M., et al. (2010). Determination of growth hormone secretagogue pralmorelin (GHRP-2) and its metabolite in human urine by liquid chromatography/electrospray ionization tandem mass spectrometry. Rapid Commun Mass Spectrom, 24(14), 2046-56. PMID: 20552695
- FDA. Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act (updated May 14, 2026): GHRP-2 and GHRP-6 in Category 3, nominated without adequate support; hexarelin not listed. Read October 28, 2026. FDA
- FDA. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (content current as of April 22, 2026): GHRP-2 and GHRP-6, 503B Category 2, added September 29, 2023, with their listed risks; hexarelin not listed. Read October 28, 2026. FDA
- FDA. Drugs@FDA via openFDA: no application for pralmorelin (GHRP-2), GHRP-6 or hexarelin. Searched October 28, 2026.
- Kaken Pharmaceutical. Injection GHRP Kaken 100 (pralmorelin hydrochloride) package insert, 2nd edition, revised July 2022 (JAPIC): indication, diagnosis of growth hormone deficiency, as a single intravenous injection. As read for our GHRP-2 entry, September 30, 2026.
- Frieboes, R. M., et al. (1995). Growth hormone-releasing peptide-6 stimulates sleep, growth hormone, ACTH and cortisol release in normal man. Neuroendocrinology, 61(5), 584-9. PMID: 7617137
- Arimura, H., et al. (2016). Investigation of the clinical significance of the growth hormone-releasing peptide-2 test for the diagnosis of secondary adrenal failure. Endocr J, 63(6), 533-44. PMID: 27020037
- Frieboes, R. M., et al. (2004). Hexarelin decreases slow-wave sleep and stimulates the secretion of GH, ACTH, cortisol and prolactin during sleep in healthy volunteers. Psychoneuroendocrinology, 29(7), 851-60. PMID: 15177700
- Rahim, A., et al. (1999). The effect of chronic hexarelin administration on the pituitary-adrenal axis and prolactin. Clin Endocrinol (Oxf), 50(1), 77-84. PMID: 10341859
- Laferrère, B., et al. (2005). Growth hormone releasing peptide-2 (GHRP-2), like ghrelin, increases food intake in healthy men. J Clin Endocrinol Metab, 90(2), 611-4. PMID: 15699539
- Rigamonti, A. E., et al. (1999). Six-week treatment with hexarelin in young dogs: evaluation of the GH responsiveness to acute hexarelin or GHRH administration, and of the orexigenic effect of hexarelin. Eur J Endocrinol, 141(3), 313-20. PMID: 10474131
- Bowers, C. Y., et al. (1996). GHRP-2, GHRH and SRIF interrelationships during chronic administration of GHRP-2 to humans. J Pediatr Endocrinol Metab, 9 Suppl 3, 261-70. PMID: 8887169
- Rahim, A., et al. (1998). Growth hormone status during long-term hexarelin therapy. J Clin Endocrinol Metab, 83(5), 1644-9. PMID: 9589671
- World Anti-Doping Agency. The 2026 Prohibited List, in force January 1, 2026: S2.2.4 names GHRP-1, GHRP-2 (pralmorelin), GHRP-3 to GHRP-6 and examorelin (hexarelin) among GH-releasing peptides; prohibited at all times. Read October 28, 2026. WADA
- Imbimbo, B. P., et al. (1994). Growth hormone-releasing activity of hexarelin in humans. A dose-response study. Eur J Clin Pharmacol, 46(5), 421-5. PMID: 7957536
- Chihara, K., et al. (2007). A simple diagnostic test using GH-releasing peptide-2 in adult GH deficiency. Eur J Endocrinol, 157(1), 19-27. PMID: 17609397
- Bellone, J., et al. (1995). Growth hormone-releasing effect of oral growth hormone-releasing peptide 6 (GHRP-6) administration in children with short stature. Eur J Endocrinol, 133(4), 425-9. PMID: 7581965
- Pimentel-Filho, F. R., et al. (1997). Growth hormone responses to GH-releasing peptide (GHRP-6) in hypothyroidism. Clin Endocrinol (Oxf), 46(3), 295-300. PMID: 9156038
- Borges, M. H., et al. (1997). Different effects of growth hormone releasing peptide (GHRP-6) and GH-releasing hormone on GH release in endogenous and exogenous hypercortisolism. Clin Endocrinol (Oxf), 46(6), 713-8. PMID: 9274702
- Martins, M. R., et al. (2003). GH-releasing peptide (GHRP-6)-induced ACTH release in patients with addison's disease: effect of glucocorticoid withdrawal. J Endocrinol Invest, 26(2), 143-7. PMID: 12739742
- Bisi, G., et al. (1999). Acute cardiovascular and hormonal effects of GH and hexarelin, a synthetic GH-releasing peptide, in humans. J Endocrinol Invest, 22(4), 266-72. PMID: 10342360
- Bisi, G., et al. (1999). Cardiac effects of hexarelin in hypopituitary adults. Eur J Pharmacol, 381(1), 31-8. PMID: 10528131
- Van den Berghe, G., et al. (2002). The combined administration of GH-releasing peptide-2 (GHRP-2), TRH and GnRH to men with prolonged critical illness evokes superior endocrine and metabolic effects compared to treatment with GHRP-2 alone. Clin Endocrinol (Oxf), 56(5), 655-69. PMID: 12030918
- Pihoker, C., et al. (1997). Treatment effects of intranasal growth hormone releasing peptide-2 in children with short stature. J Endocrinol, 155(1), 79-86. PMID: 9390009
Educational information, not medical advice. Each dose in this guide names its source, an approved label or a published study. None is a recommendation for you. An unapproved compound has no established safe or effective human dose, and products sold for “research use only” are not made or tested for people. Talk to a doctor before acting on anything on this site, including before you start, stop or change any medicine or dose.
New guides and rule changes, by email
One short email when a peptide's legal status moves — an FDA or PCAC decision, a WADA list change, an enforcement action — plus new guides and tools. At most one a week, and none when nothing changes. The newsletter has not started sending yet: your first email will be its first issue.
We keep your email address and the page you signed up from, nothing else. How it works · Privacy · RSS instead